Clarius Group LLC Buys Shares of 58,527 Haleon plc (NYSE:HLN)

Clarius Group LLC purchased a new stake in shares of Haleon plc (NYSE:HLN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 58,527 shares of the company's stock, valued at approximately $558,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. FMR LLC grew its holdings in shares of Haleon by 5.8% during the third quarter. FMR LLC now owns 104,918,269 shares of the company's stock worth $1,110,035,000 after purchasing an additional 5,768,117 shares during the last quarter. Sculptor Capital LP grew its holdings in Haleon by 67.8% during the 2nd quarter. Sculptor Capital LP now owns 8,887,098 shares of the company's stock worth $73,407,000 after acquiring an additional 3,592,000 shares during the last quarter. Clearbridge Investments LLC increased its position in Haleon by 8.6% in the 2nd quarter. Clearbridge Investments LLC now owns 41,753,987 shares of the company's stock valued at $344,888,000 after acquiring an additional 3,307,009 shares in the last quarter. Wellington Management Group LLP increased its position in Haleon by 49.9% in the 3rd quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company's stock valued at $96,833,000 after acquiring an additional 3,046,841 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Haleon by 25.3% in the third quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company's stock worth $53,791,000 after acquiring an additional 1,026,939 shares during the last quarter. 6.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on HLN shares. UBS Group raised shares of Haleon to a "strong-buy" rating in a research note on Tuesday, October 1st. Morgan Stanley lowered Haleon from an "overweight" rating to an "equal weight" rating in a research report on Friday, January 10th. Finally, Sanford C. Bernstein downgraded Haleon from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 8th. Three analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Haleon presently has a consensus rating of "Moderate Buy" and an average target price of $10.95.

Haleon Trading Up 0.5 %

Shares of NYSE:HLN traded up $0.05 during trading on Monday, hitting $9.24. 21,226,372 shares of the company's stock were exchanged, compared to its average volume of 5,607,522. The firm has a 50-day moving average price of $9.54 and a two-hundred day moving average price of $9.71. Haleon plc has a 1-year low of $7.89 and a 1-year high of $10.80. The firm has a market cap of $41.80 billion, a P/E ratio of 27.16, a PEG ratio of 2.52 and a beta of 0.29. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.